Evidence map›Paper›PMID 42203850›Full record

ArticleScientific reports2026

Effects of septic shock vasopressors on the fitness of Escherichia coli.

Prabakar Vaittinada Ayar, Antoine Bridier-Nahmias, Pradeebane Vaittinada Ayar, Alice Blet, Paul-Louis Woerther, Erick Denamur, Feriel Azibani, Hervé Jacquier

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Prabakar Vaittinada AyarUniversité Paris Cité, IAME UMR 1137, INSERM, Paris, 75018, France.
Antoine Bridier-NahmiasUniversité Paris Cité, IAME UMR 1137, INSERM, Paris, 75018, France.
Pradeebane Vaittinada AyarLaboratory of Signals and Systems (L2S), CentraleSupélec, CNRS, University of Paris-Saclay, Gif-sur-Yvette, France.
Alice BletDepartment of Anaesthesiology and Critical Care, Lyon Hepatology Institute, IHU EVEREST, Croix Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.
Paul-Louis WoertherBacteriology Unit, Department of Prevention, Diagnosis, and Treatment of Infections, Henri-Mondor University Hospital, AP-HP, Creteil, 94000, France.
Erick DenamurUniversité Paris Cité, IAME UMR 1137, INSERM, Paris, 75018, France.
Feriel Azibani *Université Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France.
Hervé Jacquier *Université Paris Cité, IAME UMR 1137, INSERM, Paris, 75018, France. herve.jacquier@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Norepinephrine is a catecholamine used as a first-line vasopressor in the management of sepsis. Nevertheless, norepinephrine has been shown to increase fitness and virulence of Escherichia coli, the most predominant facultative anaerobic commensal bacterium in the vertebrate intestinal microbiota and one of the bacteria most frequently implicated in sepsis. Despite high genetic diversity within E. coli species, these effects have been studied on a limited number of archetypal strains. Moreover, the fitness effect of alternative vasopressors, angiotensin II and vasopressin, has never been studied in E. coli. Here, we aimed to explore the effect of norepinephrine, vasopressin and angiotensin II on the fitness of E. coli in stressful media mimicking body compartments (serum-SAPI and urine), using a collection of 21 strains representative of the phylogenetic diversity of the species, and E. coli 536, an urosepsis model strain. We showed that norepinephrine increased the fitness of E. coli, regardless of genetic background, virulence or site of isolation, both in serum-SAPI and urine media. Unlike norepinephrine, angiotensin II and vasopressin display low or no effects on E. coli fitness. Our results bring insights on in vitro effects of norepinephrine, vasopressin and angiotensin II on E. coli, crucial for optimizing sepsis management and guiding future in vivo studies.

Indexed as

Escherichia coliShock, SepticVasoconstrictor AgentsAngiotensin IIHumansNorepinephrineVasopressinsVirulenceAngiotensin IINorepinephrineVasoconstrictor AgentsVasopressinsAngiotensin IIEscherichia coliFitnessNorepinephrineVasopressinVasopressors

Identifiers

PMID42203850
PMCPMC13442867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.